来源：金融界 创新医疗股东高管增减持详情如下： 日期变动人变动股数成交均价变动金额(万)变动原因变动后持股数变动人与董监高的关系2025-05-30阮 光寅-100.0011.62-0.12竞价交易192.09万本人2023-06-26马建建-630000.009.5-598.50大宗交易316.01万本 人2023-06-07阮光寅-155600.0013.51-210.22竞价交易192.10万本人2023-06-06阮光寅-43700.0013.01-56.85 竞价交易207.66万本人2022-06-27陈浩东-400.005.9-0.24集中竞价0.00子女2022-06-08陈浩东 400.005.8050.23集中竞价400.00子女2022-03-30阮光寅-37500.009.36-35.10竞价交易212.04万本人2022-03- 29阮光寅-150000.008.51-127.65竞价交易215.78万本人2022-03-28阮光寅-100000.007.74-77.40竞价交易 230.79万本人2022-03-11阮光寅-272500.007.74-210.91竞价交易240.7 ...

Core Viewpoint - The ophthalmology medical concept sector has shown a positive performance, with a 1.30% increase, ranking fifth among concept sectors, driven by significant gains in several stocks [1][2]. Group 1: Sector Performance - The ophthalmology medical concept sector saw 28 stocks rise, with notable performers including Innovation Medical, *ST Jingfeng, and others reaching their daily limit up [1]. - Key gainers in the sector included Innovation Medical (+14.87%), Guanhao Biological (+8.88%), and Kanghong Pharmaceutical (+7.84%) [1]. - Conversely, the sector also experienced declines, with major losers being Skyworth Digital (-3.19%), Jincheng Pharmaceutical (-2.40%), and Doctor Eye Glasses (-2.10%) [1]. Group 2: Capital Flow - The ophthalmology medical concept sector attracted a net inflow of 208 million yuan, with 23 stocks receiving net inflows, and 8 stocks exceeding 10 million yuan in net inflow [2]. - The leading stock in terms of net capital inflow was Innovation Medical, which saw a net inflow of 378 million yuan, followed by Kanghong Pharmaceutical and Hengfeng Information with net inflows of 66.97 million yuan and 46.49 million yuan, respectively [2][3]. - The net inflow ratios for top stocks included Innovation Medical (26.37%), *ST Jingfeng (17.55%), and Hengfeng Information (13.55%) [3].

资金流向方面，今日该股主力资金净流入3.78亿元，其中，特大单净流入4.23亿元，大单资金净流出 4477.36万元。近5日主力资金净流入4.13亿元。（数据宝） 创新医疗5月30日交易公开信息 | 买/ | 会员营业部名称 | 买入金额（万 | 卖出金额（万 | | --- | --- | --- | --- | | 卖 | | 元） | 元） | | 买一 | 中泰证券股份有限公司湖北分公司 | 8276.72 | 72.58 | | 买二 | 国泰海通证券股份有限公司上海静安区新闸路证券营业 | 5555.13 | 0.00 | | | 部 | | | | 买三 | 中泰证券股份有限公司江西分公司 | 4588.25 | 1.70 | | 买四 | 机构专用 | 3475.22 | 1017.12 | | 买五 | 国盛证券有限责任公司南昌金融大街证券营业部 | 2933.15 | 10.30 | | 卖一 | 浙商证券股份有限公司杭州杭大路证券营业部 | 1.60 | 2754.54 | | 卖二 | 方正证券股份有限公司深圳翔鸽路证券营业部 | 1148.27 | 1810.42 | | 卖三 | ...

Group 1: Market Performance - The brain science sector showed strong performance on May 30, with companies like Innovation Medical and Aipeng Medical seeing significant stock price increases, with Aipeng Medical rising over 15% during trading [1][2]. Group 2: Neuralink Developments - Neuralink, Elon Musk's brain-machine interface company, completed a $600 million financing round, with a pre-financing valuation of $9 billion [3]. - Neuralink's device, Link, received "breakthrough device" designation from the FDA, aimed at helping patients with severe speech disabilities [3]. - The National Healthcare Security Administration released guidelines for pricing new neuro-system medical services, including specific pricing for invasive and non-invasive brain-machine interfaces [3]. Group 3: Institutional Insights - Brain-machine interfaces are expected to become a core technology for human-machine interaction, initially focusing on medical rehabilitation, with future applications in education, entertainment, military, and industrial sectors [4]. - The FDA's certification of Neuralink indicates a positive outlook for the clinical application of brain-machine interface devices, potentially accelerating commercialization [4]. - The establishment of a specialized pricing standard for brain-machine interface technology by the National Healthcare Security Administration addresses the challenge of rapid development versus slow implementation, creating a policy framework for pricing and quality control [4].

暗盘资金流向曝光！提前捕捉庄家建仓信号>> 脑机接口板块异动走高，创新医疗（002173）涨停，翔宇医疗、海格通信（002465）、佳禾智能 （300793）、三博脑科（301293）、九州通（600998）等跟涨。 ...

5月29日，创新医疗今日收盘10.56元，上涨1.83%，最新市净率2.64，总市值46.60亿元。 最新一期业绩显示，2025年一季报，公司实现营业收入1.93亿元，同比-3.98%；净利润-13937418.26 元，同比-368.03%，销售毛利率8.96%。 序号股票简称PE(TTM)PE(静)市净率总市值(元)8创新医疗-44.42-49.602.6446.60亿行业平均 39.3945.553.43156.67亿行业中值44.3052.552.7058.27亿1润达医疗-291.91193.172.52106.79亿2何氏眼 科-139.92-121.761.7533.36亿3*ST生物-120.25-116.909.8823.20亿4诚达药业-72.65-124.471.6334.98亿5普 瑞眼科-66.22-59.492.8460.60亿6皓宸医疗-52.07-62.636.1823.60亿7国际医学-45.20-45.453.24115.51亿9金 域医学-35.08-35.921.99136.94亿10百诚医药-33.59-82.011.6943.25亿11迪安诊断-22.59-25.3 ...

Group 1 - The core viewpoint of the news is the performance and holdings of the Zhongyin Innovation Medical Mixed A fund, which has shown a recent net value increase of 2.02% and a year-to-date return of 39.18% [1] - The fund's recent performance includes a one-month return of -0.39%, a six-month return of 25.97%, and a year-to-date return ranking of 40 out of 4544 in its category [1] - The top ten stock holdings of the fund account for a total of 70.44%, with significant positions in companies such as Kelun-Botai (9.77%), Hengrui Medicine (9.39%), and Innovent Biologics (8.54%) [1] Group 2 - The Zhongyin Innovation Medical Mixed A fund was established on November 13, 2019, and as of March 31, 2025, it has a total scale of 2.613 billion yuan [1] - The fund manager, Zheng Ning, has a background in asset management and has held various positions in the industry, including roles at Taikang Asset Management and Zhonggeng Fund Management [2] - Zheng Ning has been managing the Zhongyin Innovation Medical Mixed A fund since July 1, 2022, and has also taken on management roles for other funds within the Zhongyin family [2]

Group 1 - The core point of the article highlights the performance of the Zhongyin Innovation Medical Mixed Fund C, which has a latest net value of 1.6494 yuan, reflecting a decrease of 2.04% [1] - The fund's performance over the past month shows a return of -0.28%, ranking 3221 out of 3909 in its category; over the past six months, it has achieved a return of 25.90%, ranking 82 out of 3796; and since the beginning of the year, it has returned 39.14%, ranking 35 out of 3832 [1] - The top ten stock holdings of the fund account for a total of 70.44%, with significant positions in companies such as Kelun-Botai (9.77%), Hengrui Medicine (9.39%), and Innovent Biologics (8.54%) [1] Group 2 - The Zhongyin Innovation Medical Mixed Fund C was established on October 30, 2020, and as of March 31, 2025, it has a total scale of 1.454 billion yuan [1] - The fund manager, Zheng Ning, has a background in asset management and has held various positions in the industry, including roles at Taikang Asset Management and Zhonggeng Fund Management [2] - Zheng Ning has been managing the Zhongyin Innovation Medical Mixed Fund C since July 1, 2022, and has also taken on management roles for other funds within the company [2]

Group 1 - The company approved a guarantee for its wholly-owned subsidiary, Zhejiang Hongrun Pharmaceutical Co., Ltd., to secure a loan of up to 8 million yuan from China Merchants Bank [1][2] - The total amount of guarantees provided by the company to its subsidiaries, including this new guarantee, is 54 million yuan, which accounts for 3.04% of the company's most recent audited net assets [2] - There are no overdue guarantees or guarantees involving litigation, and all guarantees are exclusively for subsidiaries [2] Group 2 - The company signed an irrevocable maximum guarantee agreement with China Merchants Bank, which includes various fees and costs related to the guarantee [1][2] - The guarantee period extends for three years beyond the expiration of any specific credit extension [2] - The company has disclosed the relevant announcement in multiple financial publications and on its official information platform [1]

证券代码：002173 证券简称：创新医疗 公告编号：2025-028 创新医疗管理股份有限公司 关于为鸿润医药提供担保的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本次担保情况概述 近日，公司与招商银行诸暨支行签署了《最高额不可撤销担保书》（合同编 号：571XY250512T00000101），具体内容如下： 1、债权人：招商银行股份有限公司绍兴诸暨支行 创新医疗管理股份有限公司（以下简称"公司"）于 2025 年 5 月 14 日召开 的第六届董事会 2025 年第三次临时会议审议通过了《关于为鸿润医药提供担保 的议案》，同意公司为全资控股子公司浙江鸿润医药有限公司（以下简称"鸿润 医药"）在 800 万元授信额度内向招商银行股份有限公司绍兴诸暨支行（以下简 称"招商银行诸暨支行"）申请贷款提供担保。具体内容详见公司于 2025 年 5 月 15 日披露于《证券时报》、《证券日报》、《上海证券报》、《中国证券报》和巨 潮资讯网（www.cninfo.com.cn）的相关公告。 2、保证人：创新医疗管理股份有限公司 二、担保进展情况 3、 ...